NCT03678883 2026-04-039-ING-41 in Patients With Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06385925 2025-12-15A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D MutationTyligand Pharmaceuticals (Suzhou) LimitedPhase 1/2 Recruiting440 enrolled
NCT02495896 2025-11-10Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid TumorsUniversity of Southern CaliforniaPhase 1 Active not recruiting61 enrolled
NCT03884556 2025-07-02TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced CancersTrishula Therapeutics, Inc.Phase 1 Completed56 enrolled 19 charts
NCT04731467 2024-12-27A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid TumorsPurple Biotech Ltd.Phase 1/2 Completed79 enrolled